Nurith Aizenman

Only one company makes the currently used monkeypox vaccine. Supply is limited in wealthy nations like the U.S. Less well-off nations, like Nigeria, where the outbreak began, have no vaccines at all.

Only one company makes the currently used monkeypox vaccine. Supply is limited in wealthy nations like the U.S. Less well-off nations, like Nigeria, where the outbreak began, have no vaccines at all.

How Sotiris Missailidis, head of R&D in Brazil’s vaccine agency, used the COVID crisis to push through a game-changing effort for middle-income countries to invent their own mRNA vaccine.

How Sotiris Missailidis, head of R&D in Brazil’s vaccine agency, used the COVID crisis to push through a game-changing effort for middle-income countries to invent their own mRNA vaccine.

How Sotiris Missailidis, head of R&D in Brazil’s vaccine agency, used the COVID crisis to push through a game-changing effort for middle-income countries to invent their own mRNA vaccine.

As the U.S. and Europe spearhead COVID vaccines, other regions are left struggling to gain access. But now scientists from Latin America and Africa are collaborating on mRNA technology.

As the U.S. and Europe spearhead COVID vaccines, other regions are left struggling to gain access. But now scientists from Latin America and Africa are collaborating on mRNA technology.

As the U.S. and Europe spearhead COVID vaccines, other regions are left struggling to gain access. But now scientists from Latin America and Africa are collaborating on mRNA technology.

As the U.S. and Europe spearhead COVID vaccines, other regions are left struggling to gain access. But now scientists from Latin America and Africa are collaborating on mRNA technology.

As the U.S. and Europe spearhead COVID vaccines, other regions are left struggling to gain access. But now scientists from Latin America and Africa are collaborating on mRNA technology.